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For patients with head and neck squamous cell carcinoma
(HNSCC), overall survival remains lo w . Identification of reliable
tumour markers that reflect tumour aggressiveness could thus
provide useful tools for choosing more or less aggressive treat-
ment. In this cancer localization, induction treatment provides
marked tumour responses and numerous data have shown that
overall survival was significantly improved in patients with
complete response (Spaulding et al, 1994). This link strengthens
the need to identify those patients who are likely to exhibit a more
favourable evolution following induction treatment. Investigations
at the tumoural level can provide relevant information regarding
not only intrinsic biological aggressiveness, but also its potential
responsiveness to loco-regional curative treatments.
Previous studies by Maurizi et al (1996) and us (Dassonville
et al, 1993) have shown that tumoural expression of epidermal
growth factor receptor (EGFR) carries a strong prognostic value in
head and neck cance r. Mutations of the tumour suppressor gene
p53have been implicated in the pathogenesis of HNSCC
(Greenblatt et al, 1994). As recently pointed out by Raybaud-
Diogène and colleagues (1996), the clinical significance o f  p53
gene alterations in HNSCC is currently being debated with some
studies showing a link betwee n  p53mutations and poor clinical
outcome whereas other investigators did not find such a relation-
ship. p53plays a dual role by controlling both the tumoural cell
dynamics at the G1/S checkpoint and the programmed cell death
(Harris, 1996). Interestingl y, a recent study suggested that muta-
tions of th e p53gene are associated with an increased risk of loco-
regional failure in patients with advanced HNSCC treated with
radiotherapy (Koch et al, 1996). Most induction chemotherapy
protocols in HNSCC include 5-fluorouracil (5-FU) ( V okes et al,
1993). Previous studies by our group have shown that tumoural
activity of dihydropyrimidine dehydrogenase (DPD), the first key
enzyme of 5-FU catabolism, can be a determining factor for
predicting 5-FU responsiveness in HNSCC (Etienne et al, 1995).
Also, Johnston and co-workers (1997) concluded from a retro-
spective study that characterization of tumoural thymidylate
synthase (TS) expression may be of value in identifying HNSCC
patients who would benefit from 5-FU-based induction
chemotherapy.
In total, the above-cited parameters are potential predictors of
5-FU treatment outcome. So fa r, no study has tested their prog-
nostic values using a multifactorial approach. Our purpose was
thus to conduct a multifactorial study including the above potential
tumoural indicators of biological aggressiveness and treatment
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responsiveness to predict outcome in advanced HNSCC patients
receiving 5-FU-based induction chemotherapy. EGFR, p53, TS
activity and DPD activity were determined on tumoural biopsies
obtained at time of diagnosis in 82 patients.
MATERIAL AND METHODS
Patients
This study was conducted on 82 advanced head and neck cancer
patients (71 men, 11 women; mean age 59 ranging from 40 to 76).
Tumour localizations were as follows: oropharynx (42),
hypopharynx (20), oral cavity (11), larynx (7) and multiple local-
izations (2). Description of T staging and N staging (UICC/TNM
criteria) is presented in Table 1.
Initial treatment was either induction chemotherapy (Chem)
with cisplatin–5-FU ± folinic acid (61 patients), or concomitant
radio-chemotherapy (RChem, 21 patients). Induction chemo-
therapy consisted of 3 cycles administered at 3-week intervals.
Cisplatin (100 mg m-2, 1 mg min-1 intravenously) was adminis-
tered on day 1, with hyperhydration given for 2 h before and 4 h
after cisplatin administration. 5-FU ± folinic acid was given as a 5-
day continuous infusion from day 2 to day 6, with individual 5-FU
dose adaptation on day 4, if necessary, based on pharmacokinetics
(Santini et al, 1989). Initial 5-FU dose was 1000 mg m-2 day-1
when 5-FU was administered without folinic acid (42 patients) and
500 mg m-2 day-1 when 5-FU was administered in combination
with folinic acid (200 mg m-2 day-1 of the pure l form, 19 patients).
Concomitant RChem consisted of three cisplatin–5-FU courses at
3-week intervals, associated with continuous radiotherapy given
as two daily fractions of 1.2 Gy on primary tumour and satellite
nodes (5 days per week for 7 weeks) using Cobalt 60 or linear
accelerator photons (total dose of radiotherapy 80.4 Gy). In the
RChem group, cisplatin and 5-FU were given as described above,
with a 5-FU dose of 750 mg m-2 day-1. Following induction treat-
ment, 64 patients received a loco-regional treatment consisting
of radiotherapy alone (33 patients), surgery plus radiotherapy
(22 patients) or other modalities (nine patients).
Clinical response (tumoural and global) was evaluated 2 weeks
after completion of initial treatment, by calculating the product of
the two perpendicular lesion diameters measured by endoscopy
(UICC criteria). Complete response (CR) corresponded to the
disappearance of all clinically visible or palpable lesions. Partial
response (PR) was defined as tumour regression greater than 50%.
Treatment failure corresponded to tumour regression of less than
50% or tumour progression.
Duration of survival was calculated from the date of initial diag-
nosis. For specific survival, the end-point was any cancer-related
death. Only three patients were lost to follow-up and were considered
as censored observations in survival analyses. At time of analysis, 46
patients had died. Median follow-up was 25 months for the whole
population and 40 months for alive patients.
Tumoural investigations
Tumoural biopsies correspond to a part of the tumour sample
obtained for diagnosis purpose (30–70 mg). Tumour samples were
obtained at time of diagnosis and were stored in liquid nitrogen until
assayed. Tumoural biopsies were homogenized in Tris-HCl buffer.
Differential centrigurations allowed the separation of crude
membranes from the cytosol. DPD activity, TS activity and p53
protein content were measured on the cytosol. EGFR was assayed
on the membrane preparation of the same tumoural sample using a
method that we previously published (Santini et al, 1991), based on
competition between 125I-EGF and unlabelled EGF (human recom-
binant EGF); sensitivity limit was 1 fmol mg-1 protein and inter-day
reproducibility was 11%. DPD activity was measured by means of a
radioenzymatic assay initially described by Harris et al (1990) and
modified by us (Beck et al, 1994), using 14C-5-FU as substrate;
sensitivity limit was 10 pmol min-1 mg-1 protein and inter-day
reproducibility was 10%. TS activity was assayed by means of the
tritium-release assay (Spears et al, 1988), modified by us, with
3H-dUMP as substrate; sensitivity limit was 10 fmol min-1 mg-1
protein and inter-day reproducibility was 15%. The p53 protein
level (wild-type and mutated forms) was determined using a mono-
clonal two-site single incubation immunoluminometric assay (LIA-
mat, Sangtec, Sweden), sensitivity limit was 0.002 ng mg-1 and
inter-day reproducibility was 8%.
Statistics
Gaussian distribution was evaluated according to normal proba-
bility plot and Kolmogorov–Smirnov good-fit test. Comparison
of tumoural parameters according to treatment response was
performed using Mann–Whitney test in each treatment group sepa-
rately. Overall survival and specific survival were computed using
the Kaplan–Meier method. The influence of each predictor variable
on specific survival was analysed according to the Cox propor-
tional hazard regression stratified on treatment group (Chem vs
RChem). Selection of predictors in multivariate analyses was done
by stepwise analyses (forward and backward, based on the
maximum partial likelihood estimates) stratified on treatment
group. Probability for entry and removal was 0.05 and 0.10 respec-
tively. T staging (T1-2-3 vs T4), N staging (N0 vs N1 vs N2 vs N3,
with N0 being the reference group) and treatment response (PR +
failure vs CR) were analysed as categorial variables. Continuous
variables were EGFR (log 10), DPD (log 10), TS (log 10) and p53
(log 10). These variables were also analysed as categorial variables
(0 if lower than threshold, 1 if greater) after estimation of a
threshold defined as the significant one giving the greater Wald
value in the Cox regression model. For that purpose, thresholds
were tested within the first to third quartiles. For non-significant
variables, the presently reported thresholds were the median values.
Statistics were drawn up on SPSS software (Chicago, IL, USA).
RESULTS
Description of tumoural parameters
Wide variability was observed for all investigated tumoural
parameters. EGFR (mean 356, median 110, extremes ND-3927
Table 1 Description of T staging and N staging (UICC criteria)
N0 N1 N2 N3 Total
T1 0 0 1 1 2
T2 2 1 1 2 6
T3 14 5 16 3 38
T4 3 6 21 5 35
Total 19 12 39 11 812
2TN staging not available for one patient.1866 MC Etienne et al
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fmol mg-1, n = 82), p53 (mean 1.805, median 0.187, extremes ND-
24.563 ng mg-1,  n = 82) and TS (mean 4320, median 1660,
extremes ND- 81780 fmol min-1 mg-1, n = 73) exhibited typical
asymmetrical distribution, which fitted a Gaussian distribution
after logarithm transformation. Tumoural DPD activity ranged
from 27 to 567 pmol min-1 mg-1 (mean 168, median 147, n = 72). A
significant correlation was observed between log 10 EGFR and log
10 p53 (linear regression, r = 0.39, P < 0.001, n = 82, Figure 1), the
higher the EGFR level, the greater the p53 protein content. No
relationship was seen between p53 protein content and TS activity,
or between any of the other tested parameters.
Analysis of response
In the Chem group (61 patients), tumoural response was the
following: 25 CR, 22 PR, 14 failures; global response was assess-
able in 58 patients (15 CR, 23 PR, 20 failures). In the RChem
group (21 patients), tumoural response was 14 CR, three PR and
three failures (response non-assessable in one patient); global
response was assessable in 13 patients only (eight CR, one PR,
four failures). Table 2 describes EGFR, DPD, TS and p53 as a
function of response in each treatment group. Globally, median TS
was approximately twofold higher in patients with CR than in
patients with PR or failure. However, this difference did not reach
statistical significance. Regarding p53 protein, median values were
higher in non-complete responding patients, although this observa-
tion was at the limit of significance in the RChem group only
(1.033 ng mg-1 in PR + failure patients vs 0.086 ng mg-1 in CR
patients, P = 0.058).
Analysis of survival
At time of analysis, 29 patients had died from their primary cancer,
four from chemotherapy side-effects, two from another cancer,
three from non-medical causes and eight from unknown causes.
Taking into account all death causes, median overall survival was
36 months in the Chem group (30 events) and 12 months in the
RChem group (16 events). Specific survival was analysed by
considering the 33 head and neck cancer-related deaths (20 in the
Chem group, 13 in the RChem group). Table 3 illustrates
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Figure 1 Plot of the linear regression between log10 p53 and log10 EGFR
(n = 82, r = 0.39, P < 0.001)
Table 3 Univariate Cox analyses for specific survival stratified on treatment
group
Covariablea P wald eb
T staging (0 if T1-2-3, 1 if T4)b 0.002 9.3 3.56
log p53 0.033 4.6 1.45
p53 (0 if below, 1 if over 0.80 ng mg-1) 0.017 5.8 2.37
EGFR (0 if below, 1 if over 220 fmol mg-1) 0.024 5.1 2.33
Global response (0 if PR + failure, 1 if CR)b 0.0041 8.2 0.19
aTS and DPD analysed as continuous or categorial variables (below vs over
median), EGFR (continuous variable) and N staging (N0 vs N1 versus N2 vs
N3) were non-significant covariables. bWith the exception of T staging (81
patients, 32 events) and global response (71 patients, 27 events), analyses
were conducted on 82 patients (33 events). For any covariable, eb is equal to
the risk of death of a patient presenting the value Xi divided by the risk of
death of a patient presenting the value Xi-1, whatever the value of Xi. For
categorial variables, eb represents the relative risk of death between the
2 classes of the variable. When eb > 1, the risk of death rises when the
variable increases; when eb < 1, the risk of death decreases when the
variable increases.
Table 2  Description of tumoural parameters according to treatment response
Chem group RChem group
CR PR + failure CR PR + failure
EGFR N 25 36 14 6
(fmol-1/mg-1) median 104 P = 0.81 77 229 P = 0.97 213
TS N 25 31 11 5
(fmol-1/min-1/mg-1) median 1810 P = 0.29 1070 3270 P = 0.13 1660
DPD N 25 30 11 5
(pmol-1/min-1/mg-1) median 118 P = 0.067 160 188 P = 0.57 166
p53 N 25 36 14 6
(ng-1mg-1) median 0.116 P = 0.29 0.282 0.086 P = 0.058 1.033
P-value denotes the probability value of the Mann–Whitney test.Prognostic values in head and neck cancer 1867
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univariate Cox analyses stratified on treatment group. The p53
protein content taken as a continuous variable was a significant
predictor of specific survival, the lower the p53, the longer the
survival (P = 0.03, Table 3). The best discriminant p53 threshold
was at 0.80 ng mg-1 (Figure 2). EGFR was not significant as a
continuous variable; however, survival was significantly increased
in patients with EGFR below 220 fmol mg-1 (Figure 3 and Table
3). Also, specific survival was significantly related to T staging
and global response (Table 3). A multivariate stepwise analysis
stratified on treatment group including T staging, EGFR and
p53 status revealed that T staging and EGFR status were the only
independent predictors of survival (Table 4A). Relative risks were
3.68 (95% confidence interval 1.66–8.19) for T staging and 2.65
(95% confidence interval 1.28–5.50) for EGFR status. Finally, a
stepwise analysis including response to treatment revealed that T
staging, EGFR and response to treatment remained independent
significant predictors of survival (Table 4B).
DISCUSSION
During the last decade, induction treatment with chemotherapy or
radiochemotherapy in locally advanced HNSCC has been shown
to enhance loco-regional disease control, reduce metastases rate
and, very importantly, preserve anatomic function (Dimery and
Hong, 1993; Vokes et al, 1993; Lefebvre et al, 1996; Harari, 1997).
It has been demonstrated that only those patients who achieve a
complete response will benefit from the induction therapy in terms
of survival (Spaulding, 1994). However, induction treatment
strategies are not without severe side-effects and indicators of
treatment efficacy and disease evolution would appear useful
in orienting patients towards potentially successful treatment
strategies. In line with the currently administered induction
chemotherapy in advanced HNSCC, all patients of the present
study received a cisplatin–5-FU-based induction treatment (Vokes,
1993). In the 61 patients with resectable disease, such induction
chemotherapy was performed in a strategy of organ preservation.
For the 21 patients exhibiting a strictly non-resectable tumour, a
concomitant radiochemotherapy was administered. The objective
of the present study was to analyse 5-FU sensitivity markers such
as tumoral DPD and TS for which relevance for 5-FU sensitivity
has previously been suggested (Etienne et al, 1995; Johnston et al,
1997) and to investigate disease aggressiveness indicators like
EGFR (Dassonville et al, 1993) and p53 (Raybaud-Diogène et al,
1996). The drug efficacy markers presently investigated were
centred on 5-FU responsiveness. One might wonder what is the
role played by cisplatin in tumour response. Although some vari-
ability in cisplatin tumour sensitivity cannot be excluded, previous
experimental (Etienne et al, 1991) and clinical studies (Dimery
and Hong, 1993) strongly suggest that 5-FU plays the prepon-
derant role in the cisplatin–5-FU combination.
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Figure 2 Plot of cumulative specific survival according to tumoural p53
status. Solid line represents survival of patients with p53 above 0.80 ng mg-1
(25 patients, 14 events). Dotted line represents survival of patients with p53
below 0.80 ng mg-1 (57 patients, 19 events). Vertical bars indicate censored
observations. P-value of the log-rank test was 0.0035
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Figure 3 Plot of cumulative specific survival according to EGFR status.
Solid line represents survival of patients with EGFR above 220 fmol mg-1
(27 patients, 15 events). Dotted line represents survival of patients with
EGFR below 220 fmol mg-1 (55 patients, 18 events). Vertical bars indicate
censored observations. P-value of the log-rank test was 0.0012
Table 4 Stepwise multivariate Cox analyses for specific survival stratified
on treatment group
Covariables P wald eb
A T staging (0 if T1-2-3, 1 if T4) 0.0014 10.2 3.68
EGFR (0 if below, 1 if over 220 fmol mg-1) 0.0089 6.9 2.65
p53 (0 if below, 1 if over 0.80 ng mg-1)N S
B T staging (0 if T1-2-3, 1 if T4) 0.0027 9.0 3.72
EGFR (0 if below, 1 if over 220 fmol mg-1) 0.0071 7.3 3.12
p53 (0 if below, 1 if over 0.80 ng mg-1)N S
Global response (0 if PR + failure, 1 if CR) 0.0051 7.8 0.15
Analysis A included tumoural parameters only (81 patients, 32 events).
Analysis B included tumoural parameters and response to treatment (70
patients, 26 events). eb represents the relative risk of death between the 2
classes of the variable. When eb > 1, the risk of death rises when the variable
increases; when eb < 1, the risk of death decreases when the variable
increases.1868 MC Etienne et al
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The impact of 5-FU catabolism within the target cell in 5-FU
resistance had already been pointed out by investigating DPD
activity in tumour cells. Experimental data on 19 human cancer
cell lines exhibiting spontaneous sensitivity to 5-FU showed that
the smaller the DPD activity, the greater the 5-FU sensitivity (Beck
et al, 1994). This relationship was further confirmed at the clinical
level on 62 HNSCC patients (Etienne et al, 1995). In the present
study, tumoural DPD activity was not significantly different
between responding and non-responding patients, nor was it
significant as a survival indicator. In our previous study (Etienne
et al, 1995), the predictive value of DPD was demonstrated
after normalization of the tumoural DPD activity by the activity
measured in normal tissue. Such normalization (determination of
the tumoural/non-tumoural activity ratio) was not feasible in the
present work for ethical reasons. Present results highlight the fact
that a single determination of DPD activity in the tumoural area
does not permit prediction of 5-FU responsiveness.
A recent study by Johnston and colleagues (1997) performed in
advanced HNSCC patients suggested that an elevated tumoural
TS (immunostaining assay) may be of value in identifying
patients who would exhibit resistance to 5-FU-based induction
chemotherapy, both in terms of treatment failure and survival. In
the present study, tumoural TS activity was unable to predict
patient survival or treatment efficacy. Unexpectedly, median TS
activity values were higher in complete responders as compared to
non-complete responders, even though this difference was not
significant (Table 2). Several considerations may explain this
observation. Previous data in breast (Pestalozzi et al, 1997) and
colorectal cancer (Johnston et al, 1994) have shown that the
benefit drawn from 5-FU-based chemotherapy was surprisingly
greatest in patients whose tumours had high TS expression. Also,
the method chosen by Johnston and colleagues (1997) in HNSCC
patients for TS determination differs markedly from ours, since
they used an immunohistochemical assay with visual high
observer-dependent grading. In addition, this approach does not
take into account the active status of the TS protein. For instance,
it has been shown that the TS protein can bind to p53 mRNA in
vitro (Chu and Allegra, 1996). In our study, we used a biochemical
method allowing the TS enzymatic activity itself to be measured.
The role of TS for predicting treatment efficacy in HNSCC
patients receiving 5-FU-based induction chemotherapy deserves
to be further analysed, with special attention being paid to the
analytical TS assay.
p53 protein plays a central role in cell cycle control and the apop-
totic response to cytotoxic aggressions, particularly radiation
(Harris, 1996; Hasegawa et al, 1997). Koch and co-workers (1996)
recently showed that mutations of the p53 gene are associated with
an increased risk of loco-regional failure in HNSCC patients treated
with radiotherapy. In the present study, we indirectly estimated p53
mutations by measuring the cellular retention of the p53 protein
(immunoluminometric assay) which has been demonstrated to be
markedly increased in p53-mutated cells (Raybaud-Diogène et al,
1996). The sequencing of the gene following polymerase chain
reaction (PCR) would constitute a better approach for studying p53
in HNSCC (Koch et al, 1996), but this method would be too
cumbersome to be applied on large series of patients. Among the 82
patients investigated in the present study, intratumoural levels of
p53 protein exhibited tremendous variability, with levels ranging
from the sensitivity limit (0.002 ng ml–1) up to 24.56 ng ml-1
(median 0.19). In line with the data reported by Koch and
colleagues (1996), p53 levels were lower in complete responders as
compared to non-complete responders, with a statistics close to
significance only in the group of patients receiving radiotherapy
(RChem group, Table 2). This result highlights the role of p53
status with regard to the cytotoxic effects of radiation therapy
(Hasegawa et al, 1997). More importantly, the prognostic value of
p53 was tested on specific survival, the analysis being stratified on
treatment group (Chem vs Rchem). Analysed as a continuous vari-
able, p53 protein level carries a significant prognostic value, the
lower the p53, the longer the survival (Table 3). This finding is in
full agreement with previous studies recently performed in HNSCC
patients (Raybaud-Diogène et al, 1996). An optimal cut-off value
of p53 was defined at 0.80 ng ml-1: for the 25 patients (i.e. 30.5%)
exhibiting a p53 over 0.80 ng ml-1, the risk of death was 2.37-fold
that of patients with p53 below 0.80 ng ml-1 (Table 3, Figure 2).
Apart from the well-established prognostic value of T staging,
the main indicators which showed a high prognostic value in
HNSCC over the last 5 years are p53 (Raybaud-Diogène et al,
1996) and EGFR (Dassonville et al, 1993; Störkel et al, 1993;
Maurizi et al, 1996). So far, these two parameters have been
explored separately and have never been analysed together in
a multiparametric approach for predicting outcome in HNSCC
patients. This was the main objective of the present study. We
presently confirmed the prognostic value of EGFR status (i.e.
below or over 220 fmol mg-1), specific survival increasing when
EGFR was below the threshold (Figure 3). Importantly, when
T staging, p53 status and EGFR status were entered in a multi-
variate Cox analysis stratified on treatment group, the only
independent predictors of specific survival were T staging and
EGFR status (Table 4A). Also, EGFR status remained a
strong prognostic parameter when global response was taken
into account in the multivariate Cox analysis (Table 4B).
The disappearance of the prognostic value of p53 in the pres-
ence of EGFR may be explained by the demonstrated positive
relationship between p53 levels and EGFR (Figure 1). This obser-
vation corroborates a previous work in human oesophageal squa-
mous carcinomas showing an EGFR overexpression in tumours
with p53 mutations (Rude Voldborg et al, 1997). This observation
is also in agreement with experimental data by Ludes-Meyers et al
(1996) showing that tumour-derived p53 mutants can transactivate
the EGFR promoter. In conclusion, the present multifactorial
approach, including both 5-FU sensitivity markers and disease
aggressiveness indicators to predict treatment outcome in HNSCC
patients receiving 5-FU-based induction therapy, strengthens the
high prognostic value of EGFR. This result enhances the potential
interest of current EGFR-targeted therapy for improving patient
outcome (Mendelsohn et al, 1997), particularly in patients
exhibiting high tumoural EGFR levels.
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